Metagenomi Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
MGX$0.72+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(25,039) | $(25,148) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 2,928 | 5,057 |
| Depreciation | 1,358 | 1,273 |
| Loss on fixed assets write-off | — | 4 |
| Non-cash lease expense | 1,273 | 1,126 |
| Amortization (accretion) of premiums and discounts on available-for-sale marketable securities | (1,007) | (1,221) |
| Amortization of non-cash collaboration revenue | (77) | (30) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 245 | 369 |
| Prepaid expenses and other assets | 2,237 | (938) |
| Accounts payable | 2,210 | 3,159 |
| Deferred revenue and collaboration advance | (3,049) | (10,360) |
| Accrued expenses and other current liabilities | (2,648) | (2,962) |
| Operating lease liabilities | (1,371) | (179) |
| Other non-current liabilities | 98 | — |
| Net cash used in operating activities | (22,842) | (29,850) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (288) | (915) |
| Purchases of available-for-sale marketable securities | (22,287) | (174,663) |
| Maturities of available-for-sale marketable securities | 47,303 | 80,846 |
| Net cash provided by (used in) investing activities | 24,728 | (94,732) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | — | 86,537 |
| Payment of deferred financing costs | (77) | |
| Net cash provided by (used in) financing activities | (77) | 86,537 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 1,809 | (38,045) |
| Cash, cash equivalents and restricted cash at beginning of period | 32,634 | 145,851 |
| Cash, cash equivalents and restricted cash at end of period | $34,443 | $107,806 |
| Supplemental disclosure of non-cash information | ||
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | $— | $350,758 |
| Issuance of common stock and restricted common stock in exchange for profits interests upon Reorganization | $— | $9,457 |
| Deferred initial public offering costs included in accounts payable, accrued expenses and other current liabilities | $— | $2,524 |
| Reclassification of deferred offering costs paid in prior year to stockholders’ equity | $— | $3,283 |
| Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities | $23 | $418 |
| Deferred finance issuance costs included in accounts payable, accrued expenses and other current liabilities | $422 | $— |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $29,195 | $102,558 |
| Restricted cash | 5,248 | 5,248 |
| Cash, cash equivalents and restricted cash at end of period | $34,443 | $107,806 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.